TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05309837

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polydextrose
Description: Polydextrose-enriched food products

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo-controlled
Description: Control food products
Study: NCT03654911

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG
Description: EEG

Intervention type: GENETIC
Intervention: ApoE
Description: ApoE
Study: NCT00700310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perampanel
Description: 2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perampanel
Description: 4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perampanel
Description: 8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
Study: NCT00786019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax. The program runs three times per week for about an hour each session. Gym is open Monday - Saturday during specific hours (morning, noon, evening).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (Vitamin C)
Description: During one exercise study visit, 0.06 grams of Vitamin C per kilogram fat-free mass per 100 milliliters (mL) of normal saline administered; Subjects will receive a bolus of 100mL Vitamin C solution given at 5ml/minute over 20 minutes followed by a drip-infusion given at 1.7ml/minute.
Study: NCT02739802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone(BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.Formulation number - SR16-02.
Study: NCT06669910

Intervention type: OTHER
Intervention: only assesment
Description: only assesment

Intervention type: OTHER
Intervention: only assesment
Description: only assesment

Intervention type: OTHER
Intervention: only assesment
Description: only assesment
Study: NCT02596178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography
Description: Electrical impedance tomography capitalizes on changes in electrical impendence between air-filled versus tissue or fluid-filled spaces in order to characterize and quantify regional distribution of lung volume at the bedside.
Study: NCT02759211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backwards Walking
Description: The Backwards Walking Group will perform backwards walking for the entire treatment intervention.
Study: NCT04350892

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Description: This surgery is often called gastric bypass. It is a weight-loss surgery that involves creating a small stomach pouch and bypassing part of the small intestine.~If you decide with your doctor to have gastric bypass, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the Roux-en-Y gastric bypass.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy (SG)
Description: Sleeve gastrectomy, is a weight-loss surgery that involves removing about 80% of the stomach.~If you decide with your doctor to have sleeve gastrectomy, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the sleeve gastrectomy.
Study: NCT02759211

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forwards Walking
Description: The Forwards Walking Group will perform forwards walking for the entire treatment intervention.
Study: NCT00032370

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vascular surgery with best medical treatment
Description: Patients undergo scheduled vascular surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary artery bypass grafting (CABG)
Description: Coronary artery bypass grafting prior to vascular surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Description: Cardiac revascularization via PTCA prior to vascular surgery
Study: NCT04654156

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast Boost post processing technique
Description: Contrast Enhancement Boost is a post-processing technique that uses an iodine density map generated by subtracting a pre- and post-contrast CT acquisition to artificially enhance pulmonary artery enhancement.

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast Boost post processing technique
Description: Contrast Enhancement Boost is a post-processing technique that uses an iodine density map generated by subtracting a pre- and post-contrast CT acquisition to artificially enhance pulmonary artery enhancement.
Study: NCT01866982

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Milking
Description: Umbilical cord milked toward the neonate four times at a speed of 20cm/2seconds, prior to clamping and cutting umbilical cord. Procedure takes about 10-20 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Cord Clamping
Description: Performed by positioning the baby 20 cm below the placenta for 45-60 seconds prior to umbilical cord clamping and cutting.
Study: NCT01037101

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In Vivo Exposure Therapy
Description: Three hours of exposure therapy in a high place

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In Vivo Exposure Therapy
Description: Three hours of exposure therapy in a high place

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Three hours of exposure therapy using a virtual reality system

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Three hours of exposure therapy using a virtual reality system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: 50 mg of DCS administered 30 minutes before the session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: 50 mg of DCS administered 30 minutes before the session

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 50 mg placebo administered 30 minutes before the session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50 mg placebo administered 30 minutes before the session
Study: NCT06105619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1001
Description: PLB1001 is a capsule in the form of 300mg,twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: 100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin combined with Etoposide
Description: Cisplatin:80-100mg/m2/3 days,28 days/cycle Etoposide:100mg/m2/d,3 days,28 days/cycle
Study: NCT03826771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power training
Description: high-intensity lower extremity resistance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: upper and lower body range of motion exercises
Study: NCT03783845

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: amoxicillin 500mg and metronidazole 400mg
Description: metronidazole 400mg and amoxicillin 500mg three times daily for two weeks
Study: NCT03352817

Intervention type: OTHER
Intervention: Cardiac rehabilitation
Description: A questionnaire and an information sheet are provided. The questionnaire had to be completed anonymously and individually by the patient, to avoid any influence.
Study: NCT01987661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIPAP ST
Description: non invasive ventilation, individually titrated for each patient, if necessary combined with oxygen, to improve hypercapnic respiratory failure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP ST
Description: non invasive ventilation, individually titrated for each patient, if necessary combined with oxygen, to improve hypercapnic respiratory failure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airtrap
Description: Addional to the individally titrated BiPAP ventilation parameters the function AirTrap Control is added.~AirTrap Control helps to prevent dynamic hyperinflation and makes it possible for VENTImotion 2 to automatically regulate to the best frequency and expiration time.
Study: NCT01693276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000mg/m2 given on day 1,8, and 15 of a 28 day cycle for 2 cycles prior to chemoradiation and post RT.~Gemcitabine 450 mg/m2, 30-minute infusion, given weekly during chemoradiation for a total of 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane® 100 mg/m2 given on day 1,8, and 15 of 28 day cycle for 2 cycles prior to RT and each cycle post RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: IMRT Dose escalation: 60 Gy (2 Gy/fraction)
Study: NCT03519022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
Study: NCT03102099

Intervention type: PROCEDURE
Intervention: contrast-enhanced ultrasound group
Description: The contrast-enhanced ultrasound patients will undergo biopsy with contrast-enhanced ultrasound guidance.

Intervention type: PROCEDURE
Intervention: conventional ultrasound group
Description: The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
Study: NCT03787368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790
Description: Single intravenous infusion of BAY1213790 (Two different doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790
Description: Single intravenous infusion of BAY1213790 (Two different doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: Single intravenous infusion of Placebo (0.9% sodium chloride solution)
Study: NCT04098692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib capsule
Description: 300 mg derazantinib oral administration (3x100 mg capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Derazantinib solution for infusion
Description: 100 μg \[14C\]-derazantinib intravenous administration
Study: NCT03519022

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
Study: NCT01896700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating matched dose of placebo
Study: NCT03236493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 will be administered as tablet
Study: NCT04098692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Derazantinib capsule
Description: 300 mg \[14C\]-derazantinib oral administration (3x100 mg capsules)
Study: NCT03236493

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as tablet
Study: NCT04647461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 1.5mg
Description: 1 drop 3 times a day for 12 weeks to target eyes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate 1.5mg
Description: 1 drop 3 times a day for 12 weeks to target eyes
Study: NCT03222167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir/ Grazoprevir 50/100 mg fixed dose combination
Description: Enrolled patients will be treated by Elbasvir/ Grazoprevir 50/100 mg fixed dose combination during 12 week. Followed-up on week 24. SVR12 will be evaluated.
Study: NCT00065065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4mg orally twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pill that looks identical to rosiglitazone
Study: NCT00941252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical imiquimod therapy
Description: therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical imiquimod therapy
Description: therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
Study: NCT04001205

Intervention type: DRUG
Intervention: Anticoagulation Therapy
Description: Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)
Study: NCT01399021

Intervention type: OTHER
Group type: OTHER
Intervention: Early Drain Removal
Description: Drain will be removed prior to patient's discharge on the day of the surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Late Drain Removal
Description: Patient will be seen on the day following the surgery to have the drain removed
Study: NCT02264457

Intervention type: DEVICE
Group type: OTHER
Intervention: T-flex Aspheric Toric IOL

Intervention type: DEVICE
Group type: OTHER
Intervention: T-flex Aspheric Toric IOL

Intervention type: DEVICE
Group type: OTHER
Intervention: AT TORBI toric IOL

Intervention type: DEVICE
Group type: OTHER
Intervention: AT TORBI toric IOL
Study: NCT02729493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPCAM-targeted CAR-T cells
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
Study: NCT01225991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).
Study: NCT00874900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational game
Description: Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to the game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational game + motivational interview
Description: Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to this game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department (ED).Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Participant randomized to this group will receive standard care for the treatment of their asthma, including an education asthma booklet developed by Seattle Children's. Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
Study: NCT03333681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: A single intravenous administration of autologous bone marrow derived mesenchymal stem cells(1000000 to 2000000 cells/Kg)
Study: NCT05683314

Intervention type: PROCEDURE
Intervention: Tranditional open reduction and internal fixation
Description: Under navigation and bone desity projecting method assisted 3D simulation and printing for minimal invasive surgrey
Study: NCT03833453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: EMDR is a PTSD treatment that specifically addresses troubling memories of and the personal meaning of the traumatic event and consists of 12 to 18 sessions in a maximum of 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMDR
Description: EMDR is a PTSD treatment that specifically addresses troubling memories of and the personal meaning of the traumatic event and consists of 12 to 18 sessions in a maximum of 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT
Description: DBT is a treatment for personality disorders (PD) focused on emotion regulation. It takes at least one group-session per week, and one individual coaching session every two weeks, for the duration of one year.
Study: NCT02499185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nephro Check Test
Description: Urine sample

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nephro Check Test
Description: Urine sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serum creatinine measurement
Description: Blood sample

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serum creatinine measurement
Description: Blood sample
Study: NCT01269190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy
Description: Undergo evaluation of oral lesions using a high-resolution microendoscope

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multispectral Imaging
Description: Undergo evaluation of oral cavity using a widefield multispectral imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine
Description: Proflavine) used to stain the mouth tissue after initial imaging.
Study: NCT04339543

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive dual-task walking
Description: • The task will consist in walking while performing the phoneme monitoring task. The phoneme monitoring task will consist in listening to a text through headphones, and participants will be asked to i) answer ten questions regarding the content of the text after the task, and ii) count how many times two predefined words appeared in the text. During single and dual-task walking, participants will be asked to walk around the track at a speed that they feel would be comfortable while walking through the grocery store or walking to their car, with no instructions regarding the priority to give to each task (walking vs. cognitive task).
Study: NCT04232085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Preparative regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Preparative regimen
Study: NCT04350892

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Calorie Diet (VLCD)
Description: Weight loss with calorie restricted liquid diet. Participants will be placed on a 800 kcal/day diet for meal replacement (Optifast) provided by the investigator for 12 weeks. Participants will be monitored weekly by the study dietician and medical staff.
Study: NCT02972879

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic modalities: Orthotic (Group 1)
Description: participants will be instructed to remove the orthosis only two hours in the morning, two hours in the afternoon and two hours at night to avoid joint stiffness

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic modalities: LLLT (Group 2)
Description: The LLLT parameters are:~* LASER 904nm~* P: 1.5W/cm²~* 30mV/cm²~* Area 2 cm²~* 1 Joule por ponto ( in the A1 pulley)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic modalities: Paraffin (Group 3)
Description: Paraffin will be heated and maintained at 50 ° C. Participants will immerse their affected hand 10 times in heated paraffin, then they will roll up their affected hand in a towel that they will bring, after 20 minutes timed by a trained professional, the subjects will remove the towel and paraffin glove:

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection (Group 4)
Description: The injection solution is composed of 1 ml of betamethasone and 1 ml of 2% lidocaine.This group may repeat the procedure in two weeks if they report that there was no improvement of the triggering or pain.
Study: NCT05102682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise program using exoskeleton device
Description: Exercise program focused on strengthening core body muscles and balance supported by Rex exoskeleton device